- Comorbidity status and immune biomarkers predict survival in patients with resectable oral squamous cell carcinoma (OSCC).
Why this matters
- This study further supports observed associations between comorbidity status and mortality in patients with OSCC.
- 1-year OS was 88%, 3-year OS was 68%, and 5-year OS was 57%.
- 73.9% of patients had ≥1 comorbidity.
- Moderate (HR, 2.36; P=.041) and severe (HR, 4.04; P=.004) comorbidity status (Adult Comorbidity Evaluation-27 scale), as well as age >80 years (HR, 3.84; P=.001), therapeutic neck dissection (HR, 2.95; P=.010 vs elective neck dissection), and close/positive margins (HR, 1.91; P=.028), were associated with poor OS in multivariate analysis.
- The neutrophile-to-lymphocyte ratio (NLR), derived NLR (dNLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) had 64.4%, 61.4%, 77.3%, and 56.2% diagnostic performance (area under the receiver operating characteristic curve) for predicting OS.
- Optimal cutoff points of 3 for NLR, 1.9 for dNLR, 2.6 for LMR, and 66 for PLR were identified.
- None of these markers was significantly associated with OS in multivariate analysis.
- 215 patients with resectable OSCC were included.
- Funding: None disclosed.
- Retrospective study.